RxDoctor Payments Data

Blake Singletary, DO

Interventional Cardiology · Sarasota, FLNPI 1316341787

Payments from drug & device makers

$9,460in general payments, 2019–2025

Across 255 payments — averaging $37.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$3K
  • Cardiovascular Systems Inc.$1K
  • Terumo Medical Corporation$532
  • Novartis$458
  • Bolton Medical Inc$424
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$399
  • plus $4K from 25 others

What the payments were for

  • Food & beverage$9,09396%
  • Education$3674%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,460 in reported general payments places this provider in the 45th percentile of 623 interventional cardiology providers in Florida.

See all interventional cardiology providers in Florida

Medicare billing

Part B allowed, 2024
$156,383
Medicare patients
586
Services billed
1,453

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban77$79,125
JardianceEmpagliflozin69$72,166
Diltiazem 12hr ErDiltiazem Hcl16$5,576
Ranolazine ErRanolazine12$2,844
Torsemide136$2,597
Metoprolol Succinate83$1,423
Atorvastatin Calcium89$1,200
Amlodipine Besylate212$1,155
Carvedilol121$1,034
Dilt-XrDiltiazem Hcl22$931
Midodrine Hcl15$918
Metoprolol Tartrate112$701
Rosuvastatin Calcium51$690
ClopidogrelClopidogrel Bisulfate50$514
Isosorbide Mononitrate ErIsosorbide Mononitrate28$335

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$391$79,12577 claims
Boehringer IngelheimJardiance$227$72,16669 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 623 interventional cardiology providers in Florida.

Other interventional cardiology in Sarasota

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →